Continuous Bio-Manufacturing Skid Market Report 2026

Continuous Bio-Manufacturing Skid Market Overview

• Continuous Bio-Manufacturing Skid market size has reached to $1.99 billion in 2025 • Expected to grow to $3.73 billion in 2030 at a compound annual growth rate (CAGR) of 13.3% • Growth Driver: The Increasing Demand For Biopharmaceuticals Driving The Growth Of Due To Rising Chronic And Genetic Diseases • Market Trend: Next-Generation Biologics Platforms Revolutionize Efficiency, Quality, And Cost In Drug Manufacturing • North America was the largest region in 2025.

What Is Covered Under Continuous Bio-Manufacturing Skid Market?

A continuous bio-manufacturing skid is a compact, pre-assembled system designed to carry out continuous production of biologics, integrating unit operations such as fermentation, purification, and formulation in a seamless workflow. It enables automated, scalable, and efficient biomanufacturing while minimizing manual intervention and process variability. The main product types of continuous bio-manufacturing skids are single-use skids, multi-use skids, and modular skids. Single-use skids refer to a fully integrated, disposable system designed for the uninterrupted production of biologics, where all components that contact the product are single-use, minimizing cross-contamination and cleaning requirements while enabling continuous upstream or downstream processing. These skids support various processes such as upstream, downstream, and integrated. They are utilized across a range of applications, including biopharmaceutical production, vaccine manufacturing, enzyme production, cell and gene therapy, and others and serve diverse end users, including pharmaceutical companies, biotechnology companies, contract manufacturing organizations, research institutes, and other end users.

What Is The Continuous Bio-Manufacturing Skid Market Growth Forecast?

The continuous bio-manufacturing skid market size is expected to see rapid growth in the next few years. It will grow to $3.73 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing deployment of fully continuous biologics production, rising investments in advanced bioprocess automation, growing demand for rapid scale-up capabilities, expansion of cell and gene therapy manufacturing, increasing focus on cost-efficient biologics production. Major trends in the forecast period include increasing adoption of continuous and integrated bioprocessing skids, rising demand for modular and plug-and-play manufacturing systems, growing use of real-time process monitoring and control, expansion of single-use continuous biomanufacturing platforms, enhanced focus on process efficiency and throughput.

Global Continuous Bio-Manufacturing Skid Market Segmentation

1) By Product Type: Single-Use Skids, Multi-Use Skids, Modular Skids 2) By Process: Upstream, Downstream, Integrated 3) By Application: Biopharmaceutical Production, Vaccine Manufacturing, Enzyme Production, Cell And Gene Therapy, Other Applications 4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Institutes, Other End-Users Subsegments: 1) By Single-Use Skids: Perfusion Bioreactor Skid, Tangential Flow Filtration Skid, Chromatography Skid, Buffer Preparation Skid 2) By Multi-Use Skids: Fed-Batch Bioreactor Skid, Downstream Purification Skid, Ultrafiltration Skid, Viral Inactivation Skid 3) By Modular Skid: Plug And Play Bioreactor Skid, Integrated Downstream Skid, Automated Sampling Skid, Real-Time Monitoring Skid

What Is The Driver Of The Continuous Bio-Manufacturing Skid Market?

The increasing demand for biopharmaceuticals is expected to propel the growth of the continuous bio-manufacturing skid market going forward. Biopharmaceuticals refer to medicinal products produced using biological sources, such as proteins, nucleic acids, or living cells, to treat, prevent, or diagnose diseases. The increasing demand for biopharmaceuticals is primarily driven by the rising prevalence of chronic and genetic diseases, requiring advanced biologic therapies for effective treatment and management. Continuous bio-manufacturing skid enhances biopharmaceutical production by enabling streamlined, automated, and scalable processes that improve efficiency, consistency, and speed in developing complex therapies. For instance, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, the U.S. had 40 FDA-approved biosimilar products by 2023, with 25 available on the market. In comparison, as of January 2022, there were 33 FDA-approved biosimilars, of which 21 were commercially available. Therefore, the increasing demand for biopharmaceuticals is driving the growth of the continuous bio-manufacturing skid industry.

Key Players In The Global Continuous Bio-Manufacturing Skid Market

Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.

Global Continuous Bio-Manufacturing Skid Market Trends and Insights

Major companies in the continuous bio-manufacturing skid market are focusing on developing innovative solutions, such as next-generation biologics manufacturing platforms, to enhance efficiency, scalability, and product quality. Next-generation biologics manufacturing platforms are advanced systems that enable fully connected, continuous production of biologics with real-time monitoring, higher efficiency, and consistent product quality. For instance, in October 2024, Enzene Biosciences Ltd., an India-based contract development and manufacturing organization, launched EnzeneX 2.0 at CPHI Milan 2024, the next generation of its fully connected continuous manufacturing (FCCM) technology for biologics. This patented platform enables seamless, uninterrupted processing from perfusion to final drug substance. By leveraging high-titer clones and optimized cell media, it enhances productivity, increases target protein concentrations, and minimizes batch-to-batch variability. The system also incorporates process analytical technology (PAT) for real-time monitoring and control, ensuring consistent quality and operational efficiency, while offering up to a 50% reduction in production costs per gram. These platforms provide scalable, cost-effective biologics manufacturing adaptable to diverse modalities and media formulations.

What Are Latest Mergers And Acquisitions In The Continuous Bio-Manufacturing Skid Market?

In June 2023, Donaldson Company Inc., a US-based filtration technology company, acquired Univercells Technologies for $159 million (€136 million). Through this acquisition, Donaldson aims to expand its life sciences portfolio by integrating Univercells Technologies’ innovative single-use bioreactors and automated upstream platforms to deliver comprehensive and advanced biomanufacturing solutions for cell and gene therapies, vaccines, and other biologics. Univercells Technologies S.A. is a Belgium-based company that provides advanced biomanufacturing solutions featuring intensified and integrated continuous processing principles.

Regional Insights

North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Continuous Bio-Manufacturing Skid Market?

The continuous bio-manufacturing skid market consists of sales of bioprocessing equipment, monitoring and control systems, sensors, pumps, tubing assemblies, valves, mixing systems, and control panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Continuous Bio-Manufacturing Skid Market Report 2026?

The continuous bio-manufacturing skid market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the continuous bio-manufacturing skid industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.